Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia

, , , Michael S. Conte (Lead / Corresponding author), Andrew W. Bradbury, Philippe Kolh, John V. White, Florian Dick, Robert Fitridge, Joseph L. Mills, Jean Baptiste Ricco, Kalkunte R. Suresh, M. Hassan Murad, Victor Aboyans, Murat Aksoy, Vlad Adrian Alexandrescu, David Armstrong, Nobuyoshi Azuma, Jill Belch, Michel BergoeingMartin Bjorck, Nabil Chakfé, Stephen Cheng, Joseph Dawson, Eike S. Debus, Andrew Dueck, Susan Duval, Hans H. Eckstein, Roberto Ferraresi, Raghvinder Gambhir, Mauro Garguilo, Patrick Geraghty, Steve Goode, Bruce Gray, Wei Guo, Prem C. Gupta, Robert Hinchliffe, Prasad Jetty, Kimihiro Komori, Lawrence Lavery, Wei Liang, Robert Lookstein, Matthew Menard, Sanjay Misra, Tetsuro Miyata, Greg Moneta, Jose A. Munoa Prado, Alberto Munoz, Juan E. Paolini, Manesh Patel, Frank Pomposelli, Richard Powell, Peter Robless, Lee Rogers, Andres Schanzer, Peter Schneider, Spence Taylor, Melina Vega De Ceniga, Martin Veller, Frank Vermassen, Jinsong Wang, Shenming Wang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chronic limb-threatening ischemia (CLTI)is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG)are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD)in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI)is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR)hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP)and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen)has not been established. Regenerative medicine approaches (eg, cell, gene therapies)for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.

Original languageEnglish
Pages (from-to)3S-125S.e40
JournalJournal of Vascular Surgery
Volume69
Issue number6
Early online date28 May 2019
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Blood Vessels
Ischemia
Extremities
Guidelines
Amputation
Foot
Veins
Clinical Trials
Preventive Medicine
Regenerative Medicine
Gangrene
Mortality
Peripheral Arterial Disease
Toes
Smoking Cessation
Critical Care
Cell- and Tissue-Based Therapy
Genetic Therapy
Antihypertensive Agents
Prostaglandins

Keywords

  • Bypass surgery
  • Chronic limb-threatening ischemia
  • Critical limb ischemia
  • Diabetes
  • Endovascular intervention
  • Evidence-based medicine
  • Foot ulcer
  • Peripheral artery disease
  • Practice guideline

Cite this

Conte, Michael S. ; Bradbury, Andrew W. ; Kolh, Philippe ; White, John V. ; Dick, Florian ; Fitridge, Robert ; Mills, Joseph L. ; Ricco, Jean Baptiste ; Suresh, Kalkunte R. ; Murad, M. Hassan ; Aboyans, Victor ; Aksoy, Murat ; Alexandrescu, Vlad Adrian ; Armstrong, David ; Azuma, Nobuyoshi ; Belch, Jill ; Bergoeing, Michel ; Bjorck, Martin ; Chakfé, Nabil ; Cheng, Stephen ; Dawson, Joseph ; Debus, Eike S. ; Dueck, Andrew ; Duval, Susan ; Eckstein, Hans H. ; Ferraresi, Roberto ; Gambhir, Raghvinder ; Garguilo, Mauro ; Geraghty, Patrick ; Goode, Steve ; Gray, Bruce ; Guo, Wei ; Gupta, Prem C. ; Hinchliffe, Robert ; Jetty, Prasad ; Komori, Kimihiro ; Lavery, Lawrence ; Liang, Wei ; Lookstein, Robert ; Menard, Matthew ; Misra, Sanjay ; Miyata, Tetsuro ; Moneta, Greg ; Munoa Prado, Jose A. ; Munoz, Alberto ; Paolini, Juan E. ; Patel, Manesh ; Pomposelli, Frank ; Powell, Richard ; Robless, Peter ; Rogers, Lee ; Schanzer, Andres ; Schneider, Peter ; Taylor, Spence ; De Ceniga, Melina Vega ; Veller, Martin ; Vermassen, Frank ; Wang, Jinsong ; Wang, Shenming. / Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. In: Journal of Vascular Surgery. 2019 ; Vol. 69, No. 6. pp. 3S-125S.e40.
@article{8239135826764c3caf6be7a25e7073ec,
title = "Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia",
abstract = "Chronic limb-threatening ischemia (CLTI)is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG)are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD)in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI)is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR)hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP)and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen)has not been established. Regenerative medicine approaches (eg, cell, gene therapies)for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.",
keywords = "Bypass surgery, Chronic limb-threatening ischemia, Critical limb ischemia, Diabetes, Endovascular intervention, Evidence-based medicine, Foot ulcer, Peripheral artery disease, Practice guideline",
author = "Conte, {Michael S.} and Bradbury, {Andrew W.} and Philippe Kolh and White, {John V.} and Florian Dick and Robert Fitridge and Mills, {Joseph L.} and Ricco, {Jean Baptiste} and Suresh, {Kalkunte R.} and Murad, {M. Hassan} and Victor Aboyans and Murat Aksoy and Alexandrescu, {Vlad Adrian} and David Armstrong and Nobuyoshi Azuma and Jill Belch and Michel Bergoeing and Martin Bjorck and Nabil Chakf{\'e} and Stephen Cheng and Joseph Dawson and Debus, {Eike S.} and Andrew Dueck and Susan Duval and Eckstein, {Hans H.} and Roberto Ferraresi and Raghvinder Gambhir and Mauro Garguilo and Patrick Geraghty and Steve Goode and Bruce Gray and Wei Guo and Gupta, {Prem C.} and Robert Hinchliffe and Prasad Jetty and Kimihiro Komori and Lawrence Lavery and Wei Liang and Robert Lookstein and Matthew Menard and Sanjay Misra and Tetsuro Miyata and Greg Moneta and {Munoa Prado}, {Jose A.} and Alberto Munoz and Paolini, {Juan E.} and Manesh Patel and Frank Pomposelli and Richard Powell and Peter Robless and Lee Rogers and Andres Schanzer and Peter Schneider and Spence Taylor and {De Ceniga}, {Melina Vega} and Martin Veller and Frank Vermassen and Jinsong Wang and Shenming Wang",
year = "2019",
month = "6",
doi = "10.1016/j.jvs.2019.02.016",
language = "English",
volume = "69",
pages = "3S--125S.e40",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Elsevier",
number = "6",

}

Conte, MS, Bradbury, AW, Kolh, P, White, JV, Dick, F, Fitridge, R, Mills, JL, Ricco, JB, Suresh, KR, Murad, MH, Aboyans, V, Aksoy, M, Alexandrescu, VA, Armstrong, D, Azuma, N, Belch, J, Bergoeing, M, Bjorck, M, Chakfé, N, Cheng, S, Dawson, J, Debus, ES, Dueck, A, Duval, S, Eckstein, HH, Ferraresi, R, Gambhir, R, Garguilo, M, Geraghty, P, Goode, S, Gray, B, Guo, W, Gupta, PC, Hinchliffe, R, Jetty, P, Komori, K, Lavery, L, Liang, W, Lookstein, R, Menard, M, Misra, S, Miyata, T, Moneta, G, Munoa Prado, JA, Munoz, A, Paolini, JE, Patel, M, Pomposelli, F, Powell, R, Robless, P, Rogers, L, Schanzer, A, Schneider, P, Taylor, S, De Ceniga, MV & Veller, M & Vermassen, F & Wang, J & Wang, S 2019, 'Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia', Journal of Vascular Surgery, vol. 69, no. 6, pp. 3S-125S.e40. https://doi.org/10.1016/j.jvs.2019.02.016

Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. /; Conte, Michael S. (Lead / Corresponding author); Bradbury, Andrew W.; Kolh, Philippe; White, John V.; Dick, Florian; Fitridge, Robert; Mills, Joseph L.; Ricco, Jean Baptiste; Suresh, Kalkunte R.; Murad, M. Hassan; Aboyans, Victor; Aksoy, Murat; Alexandrescu, Vlad Adrian; Armstrong, David; Azuma, Nobuyoshi; Belch, Jill; Bergoeing, Michel; Bjorck, Martin; Chakfé, Nabil; Cheng, Stephen; Dawson, Joseph; Debus, Eike S.; Dueck, Andrew; Duval, Susan; Eckstein, Hans H.; Ferraresi, Roberto; Gambhir, Raghvinder; Garguilo, Mauro; Geraghty, Patrick; Goode, Steve; Gray, Bruce; Guo, Wei; Gupta, Prem C.; Hinchliffe, Robert; Jetty, Prasad; Komori, Kimihiro; Lavery, Lawrence; Liang, Wei; Lookstein, Robert; Menard, Matthew; Misra, Sanjay; Miyata, Tetsuro; Moneta, Greg; Munoa Prado, Jose A.; Munoz, Alberto; Paolini, Juan E.; Patel, Manesh; Pomposelli, Frank; Powell, Richard; Robless, Peter; Rogers, Lee; Schanzer, Andres; Schneider, Peter; Taylor, Spence; De Ceniga, Melina Vega; Veller, Martin; Vermassen, Frank; Wang, Jinsong; Wang, Shenming.

In: Journal of Vascular Surgery, Vol. 69, No. 6, 06.2019, p. 3S-125S.e40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia

AU - Conte, Michael S.

AU - Bradbury, Andrew W.

AU - Kolh, Philippe

AU - White, John V.

AU - Dick, Florian

AU - Fitridge, Robert

AU - Mills, Joseph L.

AU - Ricco, Jean Baptiste

AU - Suresh, Kalkunte R.

AU - Murad, M. Hassan

AU - Aboyans, Victor

AU - Aksoy, Murat

AU - Alexandrescu, Vlad Adrian

AU - Armstrong, David

AU - Azuma, Nobuyoshi

AU - Belch, Jill

AU - Bergoeing, Michel

AU - Bjorck, Martin

AU - Chakfé, Nabil

AU - Cheng, Stephen

AU - Dawson, Joseph

AU - Debus, Eike S.

AU - Dueck, Andrew

AU - Duval, Susan

AU - Eckstein, Hans H.

AU - Ferraresi, Roberto

AU - Gambhir, Raghvinder

AU - Garguilo, Mauro

AU - Geraghty, Patrick

AU - Goode, Steve

AU - Gray, Bruce

AU - Guo, Wei

AU - Gupta, Prem C.

AU - Hinchliffe, Robert

AU - Jetty, Prasad

AU - Komori, Kimihiro

AU - Lavery, Lawrence

AU - Liang, Wei

AU - Lookstein, Robert

AU - Menard, Matthew

AU - Misra, Sanjay

AU - Miyata, Tetsuro

AU - Moneta, Greg

AU - Munoa Prado, Jose A.

AU - Munoz, Alberto

AU - Paolini, Juan E.

AU - Patel, Manesh

AU - Pomposelli, Frank

AU - Powell, Richard

AU - Robless, Peter

AU - Rogers, Lee

AU - Schanzer, Andres

AU - Schneider, Peter

AU - Taylor, Spence

AU - De Ceniga, Melina Vega

AU - Veller, Martin

AU - Vermassen, Frank

AU - Wang, Jinsong

AU - Wang, Shenming

PY - 2019/6

Y1 - 2019/6

N2 - Chronic limb-threatening ischemia (CLTI)is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG)are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD)in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI)is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR)hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP)and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen)has not been established. Regenerative medicine approaches (eg, cell, gene therapies)for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.

AB - Chronic limb-threatening ischemia (CLTI)is associated with mortality, amputation, and impaired quality of life. These Global Vascular Guidelines (GVG)are focused on definition, evaluation, and management of CLTI with the goals of improving evidence-based care and highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of impaired perfusion rather than a continuum. CLTI is a clinical syndrome defined by the presence of peripheral artery disease (PAD)in combination with rest pain, gangrene, or a lower limb ulceration >2 weeks duration. Venous, traumatic, embolic, and nonatherosclerotic etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classification system, based on grading of Wounds, Ischemia, and foot Infection (WIfI)is endorsed. Objective hemodynamic testing, including toe pressures as the preferred measure, is required to assess CLTI. Evidence-based revascularization (EBR)hinges on three independent axes: Patient risk, Limb severity, and ANatomic complexity (PLAN). Average-risk and high-risk patients are defined by estimated procedural and 2-year all-cause mortality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP)and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization strategy is also influenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antithrombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg, spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen)has not been established. Regenerative medicine approaches (eg, cell, gene therapies)for CLTI should be restricted to rigorously conducted randomizsed clinical trials. The GVG promotes standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of excellence for amputation prevention is stressed as a key health system initiative.

KW - Bypass surgery

KW - Chronic limb-threatening ischemia

KW - Critical limb ischemia

KW - Diabetes

KW - Endovascular intervention

KW - Evidence-based medicine

KW - Foot ulcer

KW - Peripheral artery disease

KW - Practice guideline

UR - http://www.scopus.com/inward/record.url?scp=85065614180&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2019.02.016

DO - 10.1016/j.jvs.2019.02.016

M3 - Article

C2 - 31159978

AN - SCOPUS:85065614180

VL - 69

SP - 3S-125S.e40

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 6

ER -